Kwality Pharmaceuticals Successfully Completes Phase 1 of Bioequivalence Program

Kwality Pharmaceuticals Ltd. (KPL) has successfully completed Phase 1 of an extensive Bioequivalence (BE) program covering more than 30 molecules across key therapeutic segments, including Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives. The program, executed in partnership with four globally accredited Contract Research Organizations (CROs), has been structured in a phased manner to ensure efficient execution and regulatory alignment. The successful completion of Phase 1 includes Bioequivalence studies for Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B, with the dossiers now prepared for submission across regulated, semi-regulated, and Rest of the World (ROW) markets. This milestone further strengthens KPL's global regulatory footprint and commitment to expanding access to high-quality pharmaceutical products.